Ads
related to: approved monoclonal antibody drugs- Dosing & Administration
See Dosing Regimen & Preparation
Info For A New Treatment Option
- Adverse Reaction Data
View Common Adverse Reactions
& A Guide For Managing Them.
- Manage Adverse Reactions
Explore Monitoring & Management
Strategies For Adverse Reactions.
- Research Design & Data
Discover Eligibility Criteria &
Baseline Patient Characteristics.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...
A monoclonal antibody ... MAbs approved by the FDA for cancer include: [45] ... In March 2024, pemivibart, a monoclonal antibody drug, ...
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...
Toripalimab (Loqtorzi) is a humanized IgG4 monoclonal antibody against PD-1 approved in China in 2018 and in the United States in 2023. [18] [19] [20] Tislelizumab (Tevimbra) is a humanized IgG4 anti–PD-1 monoclonal antibody approved in China in 2019 and in the United States in 2024 for certain gastrointestinal cancers.
Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008, for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS". Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.